-
Article
Open AccessRole of radiomic analysis of [18F]fluoromethylcholine PET/CT in predicting biochemical recurrence in a cohort of intermediate and high risk prostate cancer patients at initial staging
To study the feasibility of radiomic analysis of baseline [18F]fluoromethylcholine positron emission tomography/computed tomography (PET/CT) for the prediction of biochemical recurrence (BCR) in a cohort of inter...
-
Article
Open AccessRenal cell carcinoma: the population, real world, and cost-of-illness
The RCC treatment landscape has evolved dramatically over the past decade. The purpose of this study is to present a real-world data estimation of RCC’s cost-of-illness for this tumour’s clinical pathway.
-
Article
The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study group
Although systemic therapy represents the standard of care for polymetastatic kidney cancer, stereotactic body radiation therapy (SBRT) may play a relevant role in the oligometastatic setting. We conducted a mu...
-
Article
Open AccessComparison of MRI, PET, and 18F-choline PET/MRI in patients with oligometastatic recurrent prostate cancer
The aims of the study were (i) to examine the PCa detection rate of 18F-choline (FCH) PET/MRI and (ii) to assess the impact of PET/MRI findings in patients with PCa who develop OMD using PSA response as a biom...
-
Article
Prostate cancer imaging: when the game gets tough, the hard one gets done!
-
Reference Work Entry In depth
Electrochemotherapy for Superficially Metastatic Melanoma
Cutaneous metastases are not unusual in the clinical course of malignant melanoma, occurring in 2–20% of patients, depending on primary tumor features and disease stage. Patients with superficially metastatic ...
-
Living Reference Work Entry In depth
Electrochemotherapy for Superficially Metastatic Melanoma
Cutaneous metastases are not unusual in the clinical course of malignant melanoma, occurring in 2–20 % of patients, depending on primary tumor features and disease stage. Patients with superficially metastatic...
